神经科

订阅

MedSci主页 / 所有栏目 / 神经科

芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果

2020-02-07 Allan MedSci原创

Lennox-Gastaut综合征芬氟拉明癫痫
关注

一家开发罕见疾病疗法的全球制药公司Zogenix今日报告了其研究性药物FINTEPLA®（ZX008，芬氟拉明口服液）的全球III期临床试验的最新结果，结果表明，FINTEPLA治疗Lennox-Gastaut综合征（LGS）达到了其主要终点，证实了FINTEPLA的剂量为0.7 mg / kg / day时显著减少了癫痫发作频率。

一家开发罕见疾病疗法的全球制药公司Zogenix今日报告了其研究性药物FINTEPLA®（ZX008，芬氟拉明口服液）的全球III期临床试验的最新结果，结果表明，FINTEPLA治疗Lennox-Gastaut综合征（LGS）达到了其主要终点，证实了FINTEPLA的剂量为0.7 mg / kg / day时显著减少了癫痫发作频率。相同剂量的FINTEPLA在关键的次要终点上也显示出与安慰剂相比的显著改善。

LGS是一种罕见且严重的癫痫病，几乎所有患者都具有高度的治疗抵抗力，且癫痫会终生发作。频繁的跌倒以及认知障碍限制了患者和护理人员的生活质量。美国科罗拉多州儿童医院副教授Kelly Knupp博士表示：“这项安慰剂对照研究证实了芬氟拉明治疗难治性LGS患者的潜力。如果获得批准，FINTEPLA可能代表了LGS治疗的新选择”。


原始出处：

http://www.globenewswire.com/news-release/2020/02/06/1981408/0/en/Zogenix-Announces-Positive-Top-line-Results-from-Global-Pivotal-Phase-3-Trial-of-FINTEPLA-for-the-Treatment-of-Lennox-Gastaut-Syndrome.html

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2089219, encodeId=7c232089219b0, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>治疗<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>的III期临床试验取得积极结果，<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a> LGS是一种罕见且严重的<a href='/topic/show?id=09f0e1554e6' target=_blank style='color:#2F92EE;'>#癫痫#</a>病, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明), TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病), TopicDto(id=71554, encryptionId=09f0e1554e6, topicName=癫痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:41:54 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072894, encodeId=d55420e289453, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Fri May 01 14:13:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649927, encodeId=38b0164992ebd, content=<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfd323942652, createdName=fusion, createdTime=Fri Aug 21 06:13:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776677, encodeId=75c51e7667736, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Thu Sep 10 14:13:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931495, encodeId=ce86193149556, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Jun 10 02:13:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652989, encodeId=cf57165298939, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Dec 24 22:13:00 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088785, encodeId=a4772088e85fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 01 23:13:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712314, encodeId=453d1e12314b2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 22 05:13:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916234, encodeId=357b19162345a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun May 03 03:13:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431754, encodeId=b5e41431e5428, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Feb 09 09:13:00 CST 2020, time=2020-02-09, status=1, ipAttribution=)]
    2022-09-20 小小医者

    #芬氟拉明#治疗#Lennox-Gastaut综合征#的III期临床试验取得积极结果，#罕见病# LGS是一种罕见且严重的#癫痫#病

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2089219, encodeId=7c232089219b0, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>治疗<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>的III期临床试验取得积极结果，<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a> LGS是一种罕见且严重的<a href='/topic/show?id=09f0e1554e6' target=_blank style='color:#2F92EE;'>#癫痫#</a>病, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明), TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病), TopicDto(id=71554, encryptionId=09f0e1554e6, topicName=癫痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:41:54 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072894, encodeId=d55420e289453, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Fri May 01 14:13:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649927, encodeId=38b0164992ebd, content=<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfd323942652, createdName=fusion, createdTime=Fri Aug 21 06:13:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776677, encodeId=75c51e7667736, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Thu Sep 10 14:13:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931495, encodeId=ce86193149556, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Jun 10 02:13:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652989, encodeId=cf57165298939, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Dec 24 22:13:00 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088785, encodeId=a4772088e85fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 01 23:13:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712314, encodeId=453d1e12314b2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 22 05:13:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916234, encodeId=357b19162345a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun May 03 03:13:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431754, encodeId=b5e41431e5428, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Feb 09 09:13:00 CST 2020, time=2020-02-09, status=1, ipAttribution=)]
    2020-05-01 许安

    #GAS#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2089219, encodeId=7c232089219b0, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>治疗<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>的III期临床试验取得积极结果，<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a> LGS是一种罕见且严重的<a href='/topic/show?id=09f0e1554e6' target=_blank style='color:#2F92EE;'>#癫痫#</a>病, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明), TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病), TopicDto(id=71554, encryptionId=09f0e1554e6, topicName=癫痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:41:54 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072894, encodeId=d55420e289453, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Fri May 01 14:13:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649927, encodeId=38b0164992ebd, content=<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfd323942652, createdName=fusion, createdTime=Fri Aug 21 06:13:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776677, encodeId=75c51e7667736, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Thu Sep 10 14:13:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931495, encodeId=ce86193149556, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Jun 10 02:13:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652989, encodeId=cf57165298939, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Dec 24 22:13:00 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088785, encodeId=a4772088e85fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 01 23:13:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712314, encodeId=453d1e12314b2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 22 05:13:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916234, encodeId=357b19162345a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun May 03 03:13:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431754, encodeId=b5e41431e5428, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Feb 09 09:13:00 CST 2020, time=2020-02-09, status=1, ipAttribution=)]
    2020-08-21 fusion

    #Lennox-Gastaut综合征#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2089219, encodeId=7c232089219b0, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>治疗<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>的III期临床试验取得积极结果，<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a> LGS是一种罕见且严重的<a href='/topic/show?id=09f0e1554e6' target=_blank style='color:#2F92EE;'>#癫痫#</a>病, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明), TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病), TopicDto(id=71554, encryptionId=09f0e1554e6, topicName=癫痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:41:54 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072894, encodeId=d55420e289453, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Fri May 01 14:13:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649927, encodeId=38b0164992ebd, content=<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfd323942652, createdName=fusion, createdTime=Fri Aug 21 06:13:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776677, encodeId=75c51e7667736, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Thu Sep 10 14:13:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931495, encodeId=ce86193149556, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Jun 10 02:13:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652989, encodeId=cf57165298939, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Dec 24 22:13:00 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088785, encodeId=a4772088e85fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 01 23:13:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712314, encodeId=453d1e12314b2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 22 05:13:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916234, encodeId=357b19162345a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun May 03 03:13:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431754, encodeId=b5e41431e5428, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Feb 09 09:13:00 CST 2020, time=2020-02-09, status=1, ipAttribution=)]
    2020-09-10 zhangfenasdf

    #芬氟拉明#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2089219, encodeId=7c232089219b0, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>治疗<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>的III期临床试验取得积极结果，<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a> LGS是一种罕见且严重的<a href='/topic/show?id=09f0e1554e6' target=_blank style='color:#2F92EE;'>#癫痫#</a>病, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明), TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病), TopicDto(id=71554, encryptionId=09f0e1554e6, topicName=癫痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:41:54 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072894, encodeId=d55420e289453, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Fri May 01 14:13:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649927, encodeId=38b0164992ebd, content=<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfd323942652, createdName=fusion, createdTime=Fri Aug 21 06:13:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776677, encodeId=75c51e7667736, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Thu Sep 10 14:13:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931495, encodeId=ce86193149556, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Jun 10 02:13:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652989, encodeId=cf57165298939, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Dec 24 22:13:00 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088785, encodeId=a4772088e85fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 01 23:13:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712314, encodeId=453d1e12314b2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 22 05:13:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916234, encodeId=357b19162345a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun May 03 03:13:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431754, encodeId=b5e41431e5428, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Feb 09 09:13:00 CST 2020, time=2020-02-09, status=1, ipAttribution=)]
    2020-06-10 kksonne

    #II期临床试验#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2089219, encodeId=7c232089219b0, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>治疗<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>的III期临床试验取得积极结果，<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a> LGS是一种罕见且严重的<a href='/topic/show?id=09f0e1554e6' target=_blank style='color:#2F92EE;'>#癫痫#</a>病, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明), TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病), TopicDto(id=71554, encryptionId=09f0e1554e6, topicName=癫痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:41:54 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072894, encodeId=d55420e289453, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Fri May 01 14:13:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649927, encodeId=38b0164992ebd, content=<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfd323942652, createdName=fusion, createdTime=Fri Aug 21 06:13:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776677, encodeId=75c51e7667736, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Thu Sep 10 14:13:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931495, encodeId=ce86193149556, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Jun 10 02:13:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652989, encodeId=cf57165298939, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Dec 24 22:13:00 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088785, encodeId=a4772088e85fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 01 23:13:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712314, encodeId=453d1e12314b2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 22 05:13:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916234, encodeId=357b19162345a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun May 03 03:13:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431754, encodeId=b5e41431e5428, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Feb 09 09:13:00 CST 2020, time=2020-02-09, status=1, ipAttribution=)]
    2020-12-24 医生2402

    #I期临床#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2089219, encodeId=7c232089219b0, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>治疗<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>的III期临床试验取得积极结果，<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a> LGS是一种罕见且严重的<a href='/topic/show?id=09f0e1554e6' target=_blank style='color:#2F92EE;'>#癫痫#</a>病, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明), TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病), TopicDto(id=71554, encryptionId=09f0e1554e6, topicName=癫痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:41:54 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072894, encodeId=d55420e289453, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Fri May 01 14:13:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649927, encodeId=38b0164992ebd, content=<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfd323942652, createdName=fusion, createdTime=Fri Aug 21 06:13:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776677, encodeId=75c51e7667736, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Thu Sep 10 14:13:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931495, encodeId=ce86193149556, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Jun 10 02:13:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652989, encodeId=cf57165298939, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Dec 24 22:13:00 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088785, encodeId=a4772088e85fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 01 23:13:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712314, encodeId=453d1e12314b2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 22 05:13:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916234, encodeId=357b19162345a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun May 03 03:13:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431754, encodeId=b5e41431e5428, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Feb 09 09:13:00 CST 2020, time=2020-02-09, status=1, ipAttribution=)]
    2020-07-01 839640778

    #I期临床试验#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2089219, encodeId=7c232089219b0, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>治疗<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>的III期临床试验取得积极结果，<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a> LGS是一种罕见且严重的<a href='/topic/show?id=09f0e1554e6' target=_blank style='color:#2F92EE;'>#癫痫#</a>病, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明), TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病), TopicDto(id=71554, encryptionId=09f0e1554e6, topicName=癫痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:41:54 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072894, encodeId=d55420e289453, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Fri May 01 14:13:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649927, encodeId=38b0164992ebd, content=<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfd323942652, createdName=fusion, createdTime=Fri Aug 21 06:13:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776677, encodeId=75c51e7667736, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Thu Sep 10 14:13:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931495, encodeId=ce86193149556, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Jun 10 02:13:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652989, encodeId=cf57165298939, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Dec 24 22:13:00 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088785, encodeId=a4772088e85fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 01 23:13:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712314, encodeId=453d1e12314b2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 22 05:13:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916234, encodeId=357b19162345a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun May 03 03:13:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431754, encodeId=b5e41431e5428, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Feb 09 09:13:00 CST 2020, time=2020-02-09, status=1, ipAttribution=)]
    2020-04-22 ms24272190615788285182

    #AST#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2089219, encodeId=7c232089219b0, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>治疗<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>的III期临床试验取得积极结果，<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a> LGS是一种罕见且严重的<a href='/topic/show?id=09f0e1554e6' target=_blank style='color:#2F92EE;'>#癫痫#</a>病, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明), TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病), TopicDto(id=71554, encryptionId=09f0e1554e6, topicName=癫痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:41:54 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072894, encodeId=d55420e289453, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Fri May 01 14:13:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649927, encodeId=38b0164992ebd, content=<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfd323942652, createdName=fusion, createdTime=Fri Aug 21 06:13:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776677, encodeId=75c51e7667736, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Thu Sep 10 14:13:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931495, encodeId=ce86193149556, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Jun 10 02:13:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652989, encodeId=cf57165298939, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Dec 24 22:13:00 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088785, encodeId=a4772088e85fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 01 23:13:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712314, encodeId=453d1e12314b2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 22 05:13:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916234, encodeId=357b19162345a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun May 03 03:13:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431754, encodeId=b5e41431e5428, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Feb 09 09:13:00 CST 2020, time=2020-02-09, status=1, ipAttribution=)]
    2020-05-03 juliusluan78

    #III#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2089219, encodeId=7c232089219b0, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>治疗<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>的III期临床试验取得积极结果，<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a> LGS是一种罕见且严重的<a href='/topic/show?id=09f0e1554e6' target=_blank style='color:#2F92EE;'>#癫痫#</a>病, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明), TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病), TopicDto(id=71554, encryptionId=09f0e1554e6, topicName=癫痫)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:41:54 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072894, encodeId=d55420e289453, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Fri May 01 14:13:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649927, encodeId=38b0164992ebd, content=<a href='/topic/show?id=69491080814' target=_blank style='color:#2F92EE;'>#Lennox-Gastaut综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10808, encryptionId=69491080814, topicName=Lennox-Gastaut综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfd323942652, createdName=fusion, createdTime=Fri Aug 21 06:13:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776677, encodeId=75c51e7667736, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Thu Sep 10 14:13:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931495, encodeId=ce86193149556, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Jun 10 02:13:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652989, encodeId=cf57165298939, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Dec 24 22:13:00 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088785, encodeId=a4772088e85fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 01 23:13:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712314, encodeId=453d1e12314b2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 22 05:13:00 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916234, encodeId=357b19162345a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun May 03 03:13:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431754, encodeId=b5e41431e5428, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Feb 09 09:13:00 CST 2020, time=2020-02-09, status=1, ipAttribution=)]
    2020-02-09 zhouqu_8

    #综合征#

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

大麻有助于减少Lennox-Gastaut综合征的癫痫发作

一项III期随机临床试验证明，大麻二酚的药物制剂联合其他抗癫痫药物有助于减少对先前治疗无反应的Lennox-Gastaut综合征患者的癫痫发作次数，包括由于肌张力突然减退而引发的癫痫发作。

NEJM：大麻二酚可显著缓解Lennox-Gastaut综合征

研究认为大麻二酚可显著减少Lennox-Gastaut综合征患者癫痫发作